Neoadjuvant FOLFOX

Phase 3Small molecule

Neoadjuvant FOLFOX is one of 11 small molecule programs targeting Locally Advanced Colon Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Colon CancerActive, not recruiting

Locally Advanced Colon CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Locally Advanced Colon Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

4 2

Beyfortus

BeiGene

Phase 3

1 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

4 4

Mitosol

UUroGen Pharma Ltd.

Phase 3

1 5

FOLFOX

AstraZeneca

Phase 3

1 6

Navmi

SSummit Therapeutics

Phase 2

1 7

Capecitabine and Trastuzumab

FFudan University

Phase 3

2 8

Serplulimab

Shanghai Henlius Biotech

Phase 2

2 9

Neoadjuvant FOLFOX

KKyungpook National University Hospital

Phase 3

1 10

Adjuvant Chemotherapy

NNizhny Novgorod Regional Clinical Oncology Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Active, not recruiting

Locally Advanced Colon Cancer

NCT03426904

Clinical

Trials by Indication[1]

Locally Advanced Colon Cancer1 trial

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Active, not recruiting·KKyungpook National University Hospital·Phase 3·NCT03426904·708 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neoadjuvant FOLFOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant FOLFOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant FOLFOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyungpook National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKyungpook National University Hospital

Neoadjuvant FOLFOX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Locally Advanced Colon Cancer1 trial

References

Drug Info

Quick Facts

Related News